参考文献 References
[1] Chen J, McKay RM, Parada LF. Malignant glioma: lessons from genomics, mouse models, and stem cells.Cell,2012;149
(1)
: 36-47.
[2] Yu X, Sun NR, Jang HT, Guo SW, Lian MX. Associations between EGFR gene polymorphisms and susceptibility to glioma: a systematic review and meta-analysis from GWAS and case-control studies.Oncotarget,2017;8
(49)
: 86877-86885.
[3] Wu Q, Peng Y, Zhao X. An Updated and Comprehensive Meta-Analysis of Association Between Seven Hot Loci Polymorphisms from Eight GWAS and Glioma Risk.Mol Neurobiol,2016;53
(7)
: 4397-4405.
[4] Yung WK. From GWAS risk foci to glioma molecular subclass.Neuro-oncology,2013;15
(5)
: 513-514.
[5] Rood BR, MacDonald TJ. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches.J Neuro-oncol,2005;75
(3)
: 267-272.
[6] Isolan GR, Ribas Filho JM, Isolan PM, Giovanini A, Malafaia O, Dini LI, Kummer A, Jr, Negrao AW. Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins.Arquivos de Neuro-psiquiatria,2005;63
(4)
: 997-1004.
[7] Wang YY, Zhang T, Li SW, Qian TY, Fan X, Peng XX, Ma J, Wang L, Jiang T. Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis.Am J Neuroradiol,2015;36
(1)
: 70-76.
[8] Panciani PP, Giordana MT, Gallone S, Muratori A, Rotunno R, Migliorati K, Spena G, Ducati A, Fontanella M. Blood-tissue analysis of TP53 polymorphisms and survival of patients with glioma.J Neurosurg Sci,2018;36
(1)
: 70-76.
[9] Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated with glioma risk and outcome.J Med Genet,2012;49
(7)
: 420-421.
[10] Zhang X, Tian Q, Wang L, Liu Y, Li B, Liang Z, Gao P, Zheng K, Zhao B, Lu H. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI.J Magnetic Resonance Imaging,2018;
.
[11] Sarma PP, Dutta D, Mirza Z, Saikia KK, Baishya BK. Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis.Molekuliarnaia Biologiia,2017;51
(2)
: 334-341.
[12] Byeon SJ, Myung JK, Kim SH, Kim SK, Phi JH, Park SH. Distinct genetic alterations in pediatric glioblastomas.Child's Nervous System,2012;28
(7)
: 1025-1032.
[13] Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, Poon WS. Genetic alterations in pediatric high-grade astrocytomas.Human Pathol,1999;30
(11)
: 1284-1290.
[14] Xiao WZ, Han DH, Wang F, Wang YQ, Zhu YH, Wu YF, Liu NT, Sun JY. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.Tumour Biol,2014;35
(7)
: 6687-6693.
[15] Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L, Song S. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis.Oncotargets,Ther 2016;9
: 3485-3492.
[16] Preusser M, Haberler C, Hainfellner JA. Malignant glioma: neuropathology and neurobiology.Wiener Medizinische Wochenschrift,2006;156
(11-12)
: 332-337.
[17] Hulleman E, Helin K. Molecular mechanisms in gliomagenesis.Adv Cancer Res,2005;94
: 1-27.
[18] Kondo T. Molecular mechanisms involved in gliomagenesis.Brain Tumor Pathol,2017;34
(1)
: 1-7.
[19] Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.Cancer Discovery,2012;2
(5)
: 458-471.
[20] Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M. TERT mutation in glioma: Frequency, prognosis and risk.J Clin Neurosci,2016;26
: 57-62.
[21] Zhang Z, Chan AK, Ding X, Li Y, Zhang R, Chen L, Liu Y, Wang Y, Xiong J, Ng HK, et al. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.Neuro-Oncol,2017;19
(7)
: 1008-1010.
[22] Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AK, Park CK, Fung KM, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.Crit Rev Oncol/Hematol,2017;120
: 1-9.
[23] Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme.Science,2008;321
(5897)
: 1807-1812.
[24] Neal A, Kwan P, O'Brien TJ, Buckland ME, Gonzales M, Morokoff A. IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.Epilepsy Behavior,2018;78
: 30-36.
[25] Whittle IR, Short DM, Deighton RF, Kerr LE, Smith C, McCulloch J. Proteomic analysis of gliomas.British J Neurosurg,2007;21
(6)
: 576-582.
[26] Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives.J Proteomics,2010;73
(10)
: 1823-1838.
[27] Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, Daemen A, Bleeker FE, Bralten LB, Kloosterhof NK, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.Cancer Res,2009;69
(23)
: 9065-9072.
[28] Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups.Cancer Res,2006;66
(1)
: 159-167.
[29] Vital AL, Tabernero MD, Castrillo A, Rebelo O, Tao H, Gomes F, Nieto AB, Resende Oliveira C, Lopes MC, Orfao A. Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.Neuro-Oncol,2010;12
(9)
: 991-1003.
[30] Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.Cancer Cell,2006;9
(3)
: 157-173.
[31] Faury D, Nantel A, Dunn SE, Guiot MC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors .J Clin Oncol ,2007 ;25
(10 )
: 1196 -1208 .
[32] Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N, Takahashi JA, Kato K. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis.Clin Cancer Res,2007;13
(24)
: 7341-7356.
[33] Frattini V, Pagnotta SM, Tala, Fan JJ, Russo MV, Lee SB, Garofano L, Zhang J, Shi P, Lewis G, et al. A metabolic function of FGFR3-TACC3 gene fusions in cancer.Nature,2018;553
(7687)
: 222-227.
[34] Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling.Cancer Science,2007;98
(2)
: 201-213.
[35] Collet B, Guitton N, Saikali S, Avril T, Pineau C, Hamlat A, Mosser J, Quillien V. Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach.Proteome,Sci 2011;9
(1)
: 16.
[36] Li J, Zhuang Z, Okamoto H, Vortmeyer AO, Park DM, Furuta M, Lee YS, Oldfield EH, Zeng W, Weil RJ. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers.Neurology,2006;66
(5)
: 733-736.
[37] Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression.Clin Cancer Res,2004;10
(3)
: 981-987.
[38] Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM. Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry.Cancer Res,2005;65
(17)
: 7674-7681.
[39] Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Holland E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations.PloS One,2009;4
(11)
: 7752.
[40] Choi JD, Lee JS. Interplay between Epigenetics and Genetics in Cancer.Genomics Informatics,2013;11
(4)
: 164-173.
[41] You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin?.Cancer Cell,2012;22
(1)
: 9-20.
[42] Liao P, Ostrom QT, Stetson L, Barnholtz-Sloan JS. Models of Epigenetic Age Capture Patterns of DNA Methylation in Glioma Associated with Molecular Subtype, Survival, and Recurrence.Neuro-Oncol,2018 Feb 8;
: .
[43] Silber JR, Bobola MS, Blank A, Chamberlain MC. O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.Biochimica Biophysica Acta,2012;1826
(1)
: 71-82.
[44] Quintavalle C, Mangani D, Roscigno G, Romano G, Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De Marinis P, Soini Y, et al. MiR-221/222 target the DNA methyltransferase MGMT in glioma cells.PloS One,2013;8
(9)
: 74466.
[45] Kreth S, Thon N, Eigenbrod S, Lutz J, Ledderose C, Egensperger R, Tonn JC, Kretzschmar HA, Hinske LC, Kreth FW. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.PloS One,2011;6
(2)
: 17156.
[46] Castelo-Branco P, Choufani S, Mack S, Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D, Merino D, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.Lancet Oncol,2013;14
(6)
: 534-542.
[47] Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, Li W, Hu B, Cheng SY, Li M. Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype.Cancer Res,2013;73
(2)
: 990-999.
[48] Podlevsky JD, Chen JJ. Evolutionary perspectives of telomerase RNA structure and function.RNA Biol,2016;13
(8)
: 720-732.
[49] Wang Y, Zhou Z, Luo H, Wu Z, Geng J, Miu W, Pu Y, Liu N, You Y, Yang Z. Combination of tamoxifen and antisense human telomerase RNA inhibits glioma cell proliferation and anti-apoptosis via suppression of telomerase activity.Mol Med Rep,2010;3
(6)
: 935-940.
[50] Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.Translational Oncol,2012;5
(1)
: 56-65.
[51] Shi Y, Wang Y, Luan W, Wang P, Tao T, Zhang J, Qian J, Liu N, You Y. Long non-coding RNA H19 promotes glioma cell invasion by deriving miR-675.PloS One,2014;9
(1)
: 86295.